Antidiabetics’ usage in type 2 diabetes mellitus: Are prescribing guidelines adhered to? A single centre study

Background and objectivesThe association of diabetic retinopathy (DR) and diabetic macular oedema (DME) with renal function in southern Chinese patients with diabetes is poorly understood. So we aimed to study the correlation between stage of DR and DME with stage of estimated glomerular filtration rate (eGFR) and stage of urine albumin-to-creatinine ratio (UACR), and to explore the systemic risk factors for DR and DME.Design and settingThis single-centre retrospective observational study was conducted from December 2017 to November 2018.Participants413 southern Chinese patients with type 2 diabetes mellitus.Outcome measuresThe correlations between stage of DR and DME with stage of eGFR/UACR were assessed by Spearman’s or χ² analyses and represented with histograms. Risk factors associated with the occurrence of DR and DME were performed by logistic regression and represented with nomograms.ResultsStage of DR had a positive correlation with stage of eGFR (r=0.264, p<0.001) and stage of UACR (r=0.542, p<0.001). With the stage of eGFR/UACR being more severe, the prevalence of DME became higher as well (both p<0.001). The risk factors for DR were DM duration (OR 1.072; 95% CI 1.032 to 1.114; p<0.001), stage of UACR (OR 2.001; 95% CI 1.567 to 2.555; p<0.001) and low-density lipoprotein (LDL) (OR 1.301; 95% CI 1.139 to 1.485; p<0.001), while risk factors for DME were stage of UACR (OR 2.308; 95% CI 1.815 to 2.934; p<0.001) and LDL (OR 1.460; 95% CI 1.123 to 1.875; p=0.008).ConclusionsAmong southern Chinese patients, stage of DR and DME were positively correlated with renal function, while stage of UACR performed a better relevance than stage of eGFR.

Download Full-text

Non-diabetic renal disease in patients with type 2 diabetes: a single centre study

Internal Medicine Journal ◽

10.1111/imj.13708 ◽

2018 ◽

Vol 48 (4) ◽

pp. 451-456 ◽

Cited By ~ 4

Author(s):

Jian-Zhen Fan ◽

Rong Wang

Keyword(s):

Type 2 Diabetes ◽

Renal Disease ◽

Single Centre ◽

Centre Study ◽

Diabetic Renal Disease ◽

Single Centre Study

Download Full-text

Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin

Open Access Macedonian Journal of Medical Sciences ◽

10.3889/oamjms.2017.193 ◽

2017 ◽

Vol 5 (7) ◽

pp. 955-962 ◽

Cited By ~ 2

Author(s):

Maryam Jameshorani ◽

Saba Sayari ◽

Narjes Kiahashemi ◽

Nima Motamed

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Diabetic Patients ◽

Open Label ◽

Type 2 Diabetic Patients ◽

Significant Difference ◽

Single Centre Study ◽

The Mean

BACKGROUND: Diabetes mellitus is a progressive disorder that often requires combination therapy.AIM: This study aimed to compare and study of add-on sitagliptin versus pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.METHODS: This 12-week, randomised, open-label and single centre study compared sitagliptin (100 mg daily, n = 80) and pioglitazone (30 mg daily, n = 80) in type 2 diabetic patients whose disease was not adequately controlled with metformin.RESULTS: The mean change in HbA1c from baseline was -1.001 ± 0.83 with sitagliptin and -0.75 ± 1.20 with pioglitazone, and there were no significant difference between groups (P = 0.132). The mean change in fasting blood sugar (FBS) was -18.48 ± 33.32 mg/dl with sitagliptin and -20.53 ± 53.97 mg/dl with pioglitazone, and there were no significant difference between groups (P = 0.773). Sitagliptin caused 1.08 ± 2.39 kg decrease in weight, whereas pioglitazone caused 0.27 ± 2.42 kg increase in weight, with a between-group difference of 0.81 kg (P < 0.001). On the other hand, in sitagliptin group, there was greater improvement in lipid profile than pioglitazone group.CONCLUSION: Sitagliptin and Pioglitazone demonstrated similar improvements in glycemic control in type 2 diabetes mellitus patients whose diabetes had been inadequately controlled with metformin. Nevertheless, sitagliptin was more effective than pioglitazone regarding lipid and body weight change.

Download Full-text